PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
PRME vs. BEAM
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between PRME and BEAM is 0.54, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.5

Performance

PRME vs. BEAM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Prime Medicine Inc. Common Stock (PRME) and Beam Therapeutics Inc. (BEAM). The values are adjusted to include any dividend payments, if applicable.

-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%AugustSeptemberOctoberNovemberDecember2025
-81.20%
-46.55%
PRME
BEAM

Key characteristics

Sharpe Ratio

PRME:

-0.67

BEAM:

-0.04

Sortino Ratio

PRME:

-0.83

BEAM:

0.52

Omega Ratio

PRME:

0.91

BEAM:

1.06

Calmar Ratio

PRME:

-0.66

BEAM:

-0.03

Martin Ratio

PRME:

-1.21

BEAM:

-0.07

Ulcer Index

PRME:

47.48%

BEAM:

40.04%

Daily Std Dev

PRME:

85.53%

BEAM:

72.94%

Max Drawdown

PRME:

-87.50%

BEAM:

-86.76%

Current Drawdown

PRME:

-86.32%

BEAM:

-82.46%

Fundamentals

Market Cap

PRME:

$379.06M

BEAM:

$1.94B

EPS

PRME:

-$2.06

BEAM:

-$1.58

Total Revenue (TTM)

PRME:

$38.57M

BEAM:

$33.45M

Gross Profit (TTM)

PRME:

$37.26M

BEAM:

$16.97M

EBITDA (TTM)

PRME:

-$153.83M

BEAM:

-$299.05M

Returns By Period

In the year-to-date period, PRME achieves a -1.03% return, which is significantly higher than BEAM's -5.48% return.


PRME

YTD

-1.03%

1M

9.47%

6M

-45.52%

1Y

-54.77%

5Y*

N/A

10Y*

N/A

BEAM

YTD

-5.48%

1M

-12.70%

6M

-9.64%

1Y

-1.06%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

PRME vs. BEAM — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PRME
The Risk-Adjusted Performance Rank of PRME is 1313
Overall Rank
The Sharpe Ratio Rank of PRME is 1313
Sharpe Ratio Rank
The Sortino Ratio Rank of PRME is 1313
Sortino Ratio Rank
The Omega Ratio Rank of PRME is 1616
Omega Ratio Rank
The Calmar Ratio Rank of PRME is 1010
Calmar Ratio Rank
The Martin Ratio Rank of PRME is 1515
Martin Ratio Rank

BEAM
The Risk-Adjusted Performance Rank of BEAM is 4444
Overall Rank
The Sharpe Ratio Rank of BEAM is 4343
Sharpe Ratio Rank
The Sortino Ratio Rank of BEAM is 4646
Sortino Ratio Rank
The Omega Ratio Rank of BEAM is 4444
Omega Ratio Rank
The Calmar Ratio Rank of BEAM is 4343
Calmar Ratio Rank
The Martin Ratio Rank of BEAM is 4444
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

PRME vs. BEAM - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for PRME, currently valued at -0.67, compared to the broader market-2.000.002.004.00-0.67-0.04
The chart of Sortino ratio for PRME, currently valued at -0.83, compared to the broader market-4.00-2.000.002.004.00-0.830.52
The chart of Omega ratio for PRME, currently valued at 0.91, compared to the broader market0.501.001.502.000.911.06
The chart of Calmar ratio for PRME, currently valued at -0.66, compared to the broader market0.002.004.006.00-0.66-0.05
The chart of Martin ratio for PRME, currently valued at -1.21, compared to the broader market-10.000.0010.0020.0030.00-1.21-0.07
PRME
BEAM

The current PRME Sharpe Ratio is -0.67, which is lower than the BEAM Sharpe Ratio of -0.04. The chart below compares the historical Sharpe Ratios of PRME and BEAM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.80-0.60-0.40-0.200.000.200.40AugustSeptemberOctoberNovemberDecember2025
-0.67
-0.04
PRME
BEAM

Dividends

PRME vs. BEAM - Dividend Comparison

Neither PRME nor BEAM has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

PRME vs. BEAM - Drawdown Comparison

The maximum PRME drawdown since its inception was -87.50%, roughly equal to the maximum BEAM drawdown of -86.76%. Use the drawdown chart below to compare losses from any high point for PRME and BEAM. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%AugustSeptemberOctoberNovemberDecember2025
-86.32%
-53.98%
PRME
BEAM

Volatility

PRME vs. BEAM - Volatility Comparison

Prime Medicine Inc. Common Stock (PRME) has a higher volatility of 23.51% compared to Beam Therapeutics Inc. (BEAM) at 18.32%. This indicates that PRME's price experiences larger fluctuations and is considered to be riskier than BEAM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%AugustSeptemberOctoberNovemberDecember2025
23.51%
18.32%
PRME
BEAM

Financials

PRME vs. BEAM - Financials Comparison

This section allows you to compare key financial metrics between Prime Medicine Inc. Common Stock and Beam Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab